Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: The CARMELINA randomized controlled trial

Christoph Wanner
, Mark E. Cooper
, Odd Erik Johansen
, Robert Toto
, Julio Rosenstock
, Darren K. McGuire
, Steven E. Kahn
, Egon Pfarr
, Sven Schnaidt
, Maximilian Von Eynatten
, Jyothis T. George
, Nicholas D. Gollop
, Nikolaus Marx
, John H. Alexander
, Bernard Zinman
, Vlado Perkovic
, on behalf of the CARMELINA investigators

Diabetes

Research output: Contribution to journal › Article › Research › peer-review

11 Citations (Scopus)

1 results

2021

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephroticrange proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial (Clinical Kidney Journal (sfaa225) DOI: 10.1093/ckj/sfaa225)
Wanner, C., Cooper, M. E., Johansen, O. E., Toto, R., Rosenstock, J., McGuire, D. K., Kahn, S. E., Pfarr, E., Schnaidt, S., von Eynatten, M., George, J. T., Gollop, N. D., Marx, N., Alexander, J. H., Zinman, B., Perkovic, V. & on behalf of the CARMELINA investigators, 1 Sept 2021, In: Clinical Kidney Journal. 14, 9, p. 2136 1 p.
Research output: Contribution to journal › Comment / Debate › Other › peer-review

Open Access